2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5328 Characteristics and outcomes of relapsed mantle cell lymphoma after autologous stem cell transplant in first remission in the current treatment era: An EBMT lymphoma working party study

Nour Moukalled, Mathilde Fekom, PhD2, Yasmina Serroukh3, Katherine Clesham4, Marek Trnený, MD, CSc, Prof.5, Raynier Devillier, PhD6, Guillaume Dachy7, Kristina Carlson, MD, PhD8, Suzanne van Dorp9, Jennifer Byrne10, Tom Van Meerten, MD, PhD11, Jennifer Clay12, Maurizio Musso, MD13, Stina Wichert14, Anne Huynh15, Vibeke Vergote16, Peter Dreger, Prof. Dr. med.17, Olivier Hermine, MD, PhD18, Ali Bazarbachi19
1 American University of Beirut Medical Center, Beirut, Lebanon
2 EBMT LWP Paris Office Hôpital Saint-Antoine, Paris, France
3 Erasmus MC Cancer Institute, Rotterdam,, Netherlands
4 University College London Hospital, London, United Kingdom
5 Charles University Hospital, Prague, Czech Republic
6 Programme de Transplantation & Therapie Cellulaire, Marseille, France
7 Cliniques Universitaires St. Luc, Brussels, Belgium
8 University Hospital | Uppsala, Uppsala, Sweden
9 Radboud University Medical Center, Nijmegen, Netherlands
10 Nottingham University Hospitals Trust, Nottingham, United Kingdom
11 University Medical Center Groningen (UMCG), Groningen, Netherlands
12 St James University Hospital Leeds, Leeds, United Kingdom
13 Ospedale La Maddalena - Dpt. Oncologico, Palermo, Italy
14 Skanes University Hospital, Lund, Sweden
15 CHU - Institut Universitaire du Cancer Toulouse, Toulouse, France
16 University Hospital Leuven, Leuven, Belgium
17 Department Medicine V, University of Heidelberg, Heidelberg, Germany
18 Necker University Hospital, Paris, France
19 American University of Beirut Medical Center, Beirut, Lebanon

Introduction

Autologous stem cell transplantation (ASCT) has been part of the standard of care for eligible patients with mantle cell lymphoma (MCL) achieving remission after frontline therapy. For patients who relapse after ASCT, prognosis has been dismal, with allogeneic transplant historically representing the only potentially curative option (Dietrich et al, Ann Oncol 2014). However, little is known about the characteristics and outcomes of patients with MCL relapsing after ASCT in first complete response (CR) or partial response (PR) in the current era where chimeric antigen receptor (CAR)-T cell therapies and Bruton kinase inhibitors (BTKi) represent standard salvage therapies.

Methods

A registry-based multicenter analysis from the European Society for Blood and Marrow Transplantation (EBMT), approved by the Lymphoma Working Party, evaluating characteristics and outcomes of patients ≥18 years with MCL relapsing after ASCT performed as part of first-line therapy within 1 year of diagnosis, exploring relapses occurring during 3 time periods: 2011-2015 (T1); 2016-2019 (T2); 2020-2024 (T3), chosen to reflect the adoption of novel agents and treatment approaches.

Results:

A total of 2873 patients with post-ASCT relapse were identified including 1108 in T1, 1002 in T2 and 763 in T3, with median time from diagnosis to ASCT being slightly shorter in recent period [6.6 months {Interquartile range (IQR) 5.7-7.9} in T3, 6.7 months (IQR 5.7-8.1) in T2 and 7.1 months (IQR 5.9-8.7) in T1; p<0.001]. Most were males (80%) and received BEAM based conditioning (68%). The median transplant year was 2011 (IQR 2009-2012) in T1, 2015 (IQR 2012-2016) in T2, and 2018 (IQR 2015-2020) in T3; p<0.001. Those who relapsed in recent years were more likely to have comorbidity index ≥3 (T3:12%, T2 :11%, T1: 7.1%; p=0.003), and to have CR at ASCT [T3 68%, T2 66% and T1 61%, p=0.004]. Importantly, median time from ASCT to relapse increased with time [T1 (29 months {IQR 12-50}), T2 (34 months {15-60}), T3 (37 months {12-68}); p<0.001], with fewer patients relapsing <24 months (POD24) [(T3 (39%), T2 (38%), T1 (44%); p=0.01]. Median age at relapse was slightly higher for those relapsing more recently [T3 63 years (IQR 57-68), T2 62 years (57-67) and T1 62 years (56-66); p<0.001]. At last follow-up, 1474 patients (51%) had died, mostly related to disease progression (73%). The 2-year overall survival (OS) from relapse increased across the 3 time periods [T1 (55.2% {IQR 52.1-58.2}), T2 (61.4% {58.2-64.5}) and T3 (64.6% {60.6-68.3})]. Survival post-relapse was worse for those who relapsed <24 months (2-year OS from relapse 39.8% (36.7-42.8) versus 72.8% (70.5-75) for those who relapsed later, with 5-year OS for the latter group exceeding 50% [53.5 % (50.6-56.3)]. Patients transplanted in PR had inferior survival compared with those transplanted in CR at ASCT (2-year OS from relapse 55.3% (52-58.6) versus 61.8% (59.4-64.2). Of note, the 5-year OS from relapse for patients with PR at ASCT was 37.8% (34.2-41.4). On multivariable analysis, OS from relapse was negatively affected by older age: HR 1.20 per 5-year increase (95% CI 1.16-1.25)], PR compared to CR at ASCT [HR PR versus CR 1.13 (95% CI 1.02-1.26)], and positively affected by more recent year of relapse [T3 and T2 versus T1 respectively HR 0.83 (95% CI 0.72-0.96); and 0.85 (95% CI 0.76-0.96)], as well as longer time to relapse post ASCT [HR for relapsing ≥24 versus <24 months (POD24) 0.43 (95% CI {0.39-0.47}].

Conclusion:

Survival from relapse after ASCT has continuously improved despite higher age and comorbidity burden, likely related to the efficacy of novel agents and salvage therapies. Time to relapse increased with time, with less POD24, likely reflecting the impact of post-transplant maintenance. This study provides a rational basis for analyzing the impact of modern salvage options, such as CARTs and novel agents on the overall outcome of first MCL relapses.

Nour Moukalled: No relevant conflicts of interest to declare.